Acura Pharmaceuticals, Inc. (ACUR) |
|
0.05 0 (0%)
|
03-24 11:19 |
|
Open: |
0.05 |
Pre. Close: |
0.05 |
|
High:
|
0.05 |
Low:
|
0.05 |
|
Volume:
|
632 |
Market Cap:
|
3(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:46 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.05 One year: 0.06 |
| Support: |
Support1: 0.05 Support2: 0.05 |
| Resistance: |
Resistance1: 0.05 Resistance2: 0.05 |
| Pivot: |
0.05 |
| Moving Average: |
MA(5): 0.05 MA(20): 0.05
MA(100): 0.04  MA(250): 0.18  |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 0 %D(3): 0 |
| RSI: |
RSI(14): 89.1 |
| 52-week: |
High: 0.55 Low: 0 |
| Average Vol(K): |
3-Month: 1 (K) 10-Days: 1 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACUR ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 84 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.05 - 0.05 |
0.05 - 0.05 |
|
Low:
|
0.05 - 0.05 |
0.05 - 0.05 |
|
Close:
|
0.05 - 0.05 |
0.05 - 0.05 |
|
Company Description |
|
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois. |
Headline News |
Wed, 15 Nov 2017
ACUR Stock Forecast, Price & News (Acura Pharmaceuticals) - MarketBeat
Sun, 12 Nov 2017
AMPE Stock Forecast, Price & News (Ampio Pharmaceuticals) - MarketBeat
Mon, 16 May 2016
Pfizer and Acura receive US FDA approval for Oxecta immediate ... - Proactive Investors UK
Fri, 03 Jul 2015
Acura Pharmaceuticals, Inc. (ACUR) Stock Price Today, Quote & News - Seeking Alpha
Tue, 10 Feb 2015
17 Healthcare Companies To Consider Based On Patent Dynamics ... - Seeking Alpha
Mon, 10 Dec 2012
Acura Pharmaceuticals Launches Next Generation Cold Medicine ... - Pharmaceutical Online
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: PNK |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
65 (M) |
| Shares Float |
61 (M) |
|
% Held by Insiders
|
19.2 (%) |
|
% Held by Institutions
|
3 (%) |
|
Shares Short
|
90 (K) |
|
Shares Short P.Month
|
76 (K) |
Stock Financials |
|
EPS
|
-0.03 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.47 |
|
EPS Est Next Year
|
0.37 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
-51.3 |
|
Operating Margin (%)
|
-49.4 |
|
Return on Assets (ttm)
|
-38.5 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
-34.1 |
|
Gross Profit (p.s.)
|
0.02 |
|
Sales Per Share
|
0.03 |
|
EBITDA (p.s.)
|
-0.02 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-1.67 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
1.44 |
|
Price to Cash Flow
|
-8.22 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
